Advisor Group Holdings, Inc. Selecta Biosciences Inc Transaction History

Advisor Group Holdings, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	N/A	-7,085 Reduced 99.13%	62 $0
Q1 2024 May 10, 2024	SELL	$0.62 - $0.85 $1,189 - $1,631	-1,919 Reduced 21.17%	7,147 $6,000
Q4 2023 Feb 12, 2024	BUY	$0.67 - $1.35 $324 - $653	484 Added 5.64%	9,066 $6,000
Q3 2023 Nov 13, 2023	BUY	$1.02 - $1.23 $765 - $922	750 Added 9.58%	8,582 $9,000
Q2 2023 Aug 10, 2023	SELL	$1.04 - $1.4 $5,208 - $7,011	-5,008 Reduced 39.0%	7,832 $8,000
Q1 2023 May 12, 2023	BUY	$1.15 - $1.89 $1,150 - $1,890	1,000 Added 8.45%	12,840 $17,000
Q4 2022 Feb 10, 2023	BUY	$0.96 - $1.6 $2,080 - $3,467	2,167 Added 22.4%	11,840 $13,000
Q3 2022 Nov 14, 2022	SELL	$1.33 - $2.6 $45,027 - $88,023	-33,855 Reduced 77.78%	9,673 $16,000
Q2 2022 Aug 10, 2022	BUY	$0.67 - $1.4 $26,805 - $56,011	40,008 Added 1136.59%	43,528 $57,000
Q2 2021 Aug 02, 2021	BUY	$2.82 - $5.01 $9,461 - $16,808	3,355 Added 2033.33%	3,520 $15,000
Q1 2021 May 13, 2021	BUY	$2.92 - $5.07 $481 - $836	165 New	165 $1,000
Q3 2020 Nov 12, 2020	SELL	$2.18 - $2.84 $218 - $284	-100 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.83 - $4.06 $183 - $405	100 New	100 $0

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.